Hua Rong Lu

Dr. Hua Rong Lu


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
HLHua Rong Lu
Hua Rong Lu
GYGan-Xin Yan
Gan-Xin Yan
DGDavid J. Gallacher
David J. Gallacher

9 September 2015 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
HLHua Rong Lu
Hua Rong Lu
RWRoss Whittaker
Ross Whittaker
JPJeffrey H. Price
Jeffrey H. Price
RVRaquel Vega
Raquel Vega
EPEmily R. Pfeiffer
Emily R. Pfeiffer
DGDavid J. Gallacher
David J. Gallacher
Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are emerging as a powerful in vitro model for cardiac safety assessment which may allow for better identification of compounds with poor arrhythmogenic liability profiles early in the drug discovery process. Here, we describe our examination of the Kinetic Image Cytometer (KIC) system’s ability to predict adverse compound effects using hiPS-CMs and a library of 53 compounds, the majority of which are known to be cardioactive compounds, and several negative controls. The KIC provides a high throughput method for analyzing intracellular calcium transients. In the cardiomyocyte, intracellular calcium transients integrate the electrochemical signals of the action potential (AP) with the molecular signaling pathways regulating contraction. Drug-induced alterations in the shape and duration of AP result in changes to the shape and duration of the intracellular calcium transient. By examining calcium transient dynamics in hiPS-CMs, KIC can be used as a phenotypic screen to assess compound effects across multiple ion channel types (MITs), detecting MITs, calcium handling and signaling effects. The results of this blinded study indicate that using hiPS-CMs, KIC is able to accurately detect drug-induced changes in Ca2+ transient dynamics (ie, duration and beat rate) and therefore, may be useful in predicting drug-induced arrhythmogenic liabilities in early de-risking within the drug discovery phase.

13 April 2010 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
HLHua Rong Lu
Hua Rong Lu
JRJutta Rohrbacher
Jutta Rohrbacher
EVEddy Vlaminckx
Eddy Vlaminckx
KAKarel Van Ammel
Karel Van Ammel
GYGan‐Xin Yan
Gan‐Xin Yan
DGDavid J Gallacher
David J Gallacher
Background and purpose:  The regulatory guidelines (ICHS7B) for the identification of only drug‐induced long QT and pro‐arrhythmias have certain limitations.Experimental approach:  Conduction time (CT) was measured in isolated Purkinje fibres, left ventricular perfused wedges and perfused hearts from rabbits, and sodium current was measured in Chinese hamster ovary cells, transfected with Nav1.5 channels.Key results:  A total of 355 compounds were screened for their effects on CT: 32% of these compounds slowed conduction, 65% had no effect and 3% accelerated conduction. Lidocaine and flecainide, which slow conduction, were tested in more detail as reference compounds. In isolated Purkinje fibres, flecainide largely slowed conduction and markedly increased triangulation, while lidocaine slightly slowed conduction and did not produce significant triangulation. Also in isolated left ventricular wedge preparations, flecainide largely slowed conduction in a rate‐dependent manner, and elicited ventricular tachycardia (VT). Lidocaine slightly slowed conduction, reduced Tp–Te and did not induce VT. Similarly in isolated hearts, flecainide markedly slowed conduction, increased Tp–Te and elicited VT or ventricular fibrillation (VF). The slowing of conduction and induction of VT/VF with flecainide was much more evident in a condition of ischaemia/reperfusion. Lidocaine abolished ischaemia/reperfusion‐induced VT/VF. Flecainide blocked sodium current (INa) preferentially in the activated state (i.e. open channel) with slow binding and dissociation rates in a use‐dependent manner, and lidocaine weakly blocked INa.Conclusion and implications:  Slowing conduction by blocking INa could be potentially pro‐arrhythmic. It is possible to differentiate between compounds with ‘good’ (lidocaine‐like) and ‘bad’ (flecainide‐like) INa blocking activities in these models.

1 November 2020 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
GGGary Gintant
Gary Gintant
EKEmily Pfeiffer Kaushik
Emily Pfeiffer Kaushik
TFTromondae Feaster
Tromondae Feaster
SSSonja Stoelzle-Feix
Sonja Stoelzle-Feix
YKYasunari Kanda
Yasunari Kanda
KBKsenia Blinova
Ksenia Blinova
Human stem cell-derived cardiomyocytes (hSC-CMs) hold great promise as in vitro models to study the electrophysiological effects of novel drug candidates on human ventricular repolarization. Two recent large validation studies have demonstrated the ability of hSC-CMs to detect drug-induced delayed repolarization and "cellrhythmias" (interrupted repolarization or irregular spontaneous beating of myocytes) linked to Torsade-de-Pointes proarrhythmic risk. These (and other) studies have also revealed variability of electrophysiological responses attributable to differences in experimental approaches and experimenter, protocols, technology platforms used, and pharmacologic sensitivity of different human-derived models. Thus, when evaluating drug-induced repolarization effects, there is a need to consider 1) the advantages and disadvantages of different approaches, 2) the need for robust functional characterization of hSC-CM preparations to define "fit for purpose" applications, and 3) adopting standardized best practices to guide future studies with evolving hSC-CM preparations. Examples provided and suggested best practices are instructional in defining consistent, reproducible, and interpretable "fit for purpose" hSC-CM-based applications. Implementation of best practices should enhance the clinical translation of hSC-CM-based cell and tissue preparations in drug safety evaluations and support their growing role in regulatory filings.

1 December 2018 in Stem Cell Reports
Verified
Journal Article
Open access
IKIvan Kopljar
Ivan Kopljar
HLHua Rong Lu
Hua Rong Lu
KAKarel Van Ammel
Karel Van Ammel
MOMartin Otava
Martin Otava
FTFetene Tekle
Fetene Tekle
DGDavid J. Gallacher
David J. Gallacher
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have emerged as a promising cardiac safety platform, demonstrated by numerous validation studies using drugs with known cardiac adverse effects in humans. However, the challenge remains to implement hiPSC-CMs into cardiac de-risking of new chemical entities (NCEs) during preclinical drug development. Here, we used the calcium transient screening assay in hiPSC-CMs to develop a hazard score system for cardiac electrical liabilities. Tolerance interval calculations and evaluation of different classes of cardio-active drugs enabled us to develop a weighted scoring matrix. This approach allowed the translation of various pharmacological effects in hiPSC-CMs into a single hazard label (no, low, high, or very high hazard). Evaluation of 587 internal NCEs and good translation to ex vivo and in vivo models for a subset of these NCEs highlight the value of the cardiac hazard scoring in facilitating the selection of compounds during early drug safety screening.

8 February 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
IKIvan Kopljar
Ivan Kopljar
ABAn De Bondt
An De Bondt
PVPetra Vinken
Petra Vinken
ATArd Teisman
Ard Teisman
BDBruce Damiano
Bruce Damiano
HLHua Rong Lu
Hua Rong Lu